NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $52.79 -0.48 (-0.90%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$52.79 0.00 (0.00%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Travere Therapeutics Stock (NASDAQ:TVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$52.63▼$55.5750-Day Range$51.80▼$67.5252-Week Range$22.59▼$68.73Volume1.98 million shsAverage Volume1.93 million shsMarket Capitalization$4.98 billionP/E RatioN/ADividend YieldN/APrice Target$69.50Consensus RatingModerate Buy Company Overview Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work centers on conditions with limited treatment options, including IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment approved in the United States for certain adults with primary IgAN who are at risk of disease progression. The company is also evaluating sparsentan and other potential therapies in additional kidney-disease indications, including FSGS, through clinical development programs. Originally founded as Retrophin, the company adopted the name Travere Therapeutics in 2020. Based in San Diego, California, Travere serves patients and healthcare professionals primarily through its U.S. commercial operations while pursuing clinical development and regulatory opportunities in international markets. Neil McFarlane serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Travere Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreTVTX MarketRank™: 3.188862621485 of 5 starsTravere Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 325th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTravere Therapeutics has a consensus price target of $69.50, representing about 31.7% upside from its current price of $52.79.Amount of Analyst CoverageTravere Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Travere Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($0.54) to $2.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -114.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -114.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 41.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.05% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 7.23.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 2.32%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.92 News SentimentTravere Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Travere Therapeutics this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $66,336,443.00 in company stock.Percentage Held by Insiders4.44% of the stock of Travere Therapeutics is held by insiders.Percentage Held by InstitutionsTravere Therapeutics has minimal institutional ownership at this time.Read more about Travere Therapeutics' insider trading history. Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVTX Stock News HeadlinesTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 12, 2026 | businesswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Price Target of $69.50October 11, 2026 | americanbankingnews.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent. | Brownstone Research (Ad)Travere to Present New Data Supporting FILSPARI as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026October 6, 2026 | marketscreener.comMKuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmSeptember 30, 2026 | prnewswire.comTravere Therapeutics (TVTX) Sets CEO Handover For December 2026September 22, 2026 | finance.yahoo.comTravere Therapeutics (TVTX) Stock May Trade Above Fair Value TodaySeptember 22, 2026 | finance.yahoo.comTravere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 5,375 SharesSeptember 18, 2026 | insidertrades.comSee More Headlines TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $38.21 at the start of the year. Since then, TVTX shares have increased by 38.2% and is now trading at $52.79. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its earnings results on Tuesday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The firm's revenue for the quarter was up 48.2% on a year-over-year basis. Read the conference call transcript. Who are Travere Therapeutics' major shareholders? Travere Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (1.22%), Insight Wealth Strategies LLC (0.10%), State of Alaska Department of Revenue and Farther Finance Advisors LLC. Insiders that own company stock include Eric M Dube, Peter Heerma, Elizabeth E Reed, Jula Inrig, William E Rote, Jeffrey A Meckler, Christopher R Cline, Gary A Lyons, Timothy Coughlin, Sandra Calvin and Roy D Baynes. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Bloom Energy (BE), CrowdStrike (CRWD), Tesla (TSLA), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST). Company Calendar Last Earnings8/04/2026Today10/15/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TVTX's financial health is in the Green zone, according to TradeSmith. TVTX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TVTX CIK1438533 Webwww.travere.com Phone(888) 969-7879Fax302-645-1280Employees497Year Founded2011Price Target and Rating Average Price Target for Travere Therapeutics$69.50 High Price Target$89.00 Low Price Target$41.00 Potential Upside/Downside+31.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.55 million Net Margins-7.35% Pretax Margin-11.34% Return on Equity-55.15% Return on Assets-6.88% Debt Debt-to-Equity Ratio24.58 Current Ratio4.05 Quick Ratio3.99 Sales & Book Value Annual Sales$490.73 million Price / Sales10.14 Cash Flow$0.36 per share Price / Cash Flow147.10 Book Value$1.28 per share Price / Book41.24Miscellaneous Outstanding Shares94,260,000Free Float90,076,000Market Cap$4.98 billion OptionableOptionable Beta1.13 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TVTX) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredStop picking AI winners. Start collecting every ThursdayOne fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution ...Investors Alley | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
